Accredited Investor? We Have a Deal Available Right Now! Click Here to Schedule a Call and Get Full Access

Life Sciences Venture Capital Monitor – Europe 08/2022 published



FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 08/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of  August 2022 we identify the following current VC trends in Europe:

  • In 2022, overall Life Sciences funding has reached EUR 6,501m so far 
  • Top 5 Deals exceed EUR 120m each, largest transaction amounted to EUR 500m in Doctolib (France)
  • Bpifrance (France) dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
  • Biotech received 43% of the total investment volume, (+1% compared to the previous month)
  • Oncology still dominates as the top indication in Biotechnology

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link




Source link

Related Articles

Article